Combined use of an alpha-adrenergic receptor antagonist and...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/18 (2006.01) A61K 31/439 (2006.01)

Patent

CA 2741721

The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2- methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl- 1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)- quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) with a substantial storage component is provided.

L'invention concerne l'utilisation combinée du composé (R)-5-(2-{[2-(2-éthoxyphénoxy)éthyl]amino}propyl)-2-méthoxybenzène-1-sulfonamide (tamsulosine) ou d'un sel pharmaceutiquement acceptable de ce composé, et du composé (lS)-1-phényl-1,2,3,4-tétrahydroisoquinoline-2-acide carboxylique (3R)-quinuclidin-3-yl ester (solifénacine) ou d'un sel pharmaceutiquement acceptable de ce composé, pour élaborer un médicament destiné à améliorer des symptômes des voies urinaires inférieures associés à une hyperplasie bénigne de la prostate (LUTS/BPH) à l'aide d'un composant de stockage sensible.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combined use of an alpha-adrenergic receptor antagonist and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined use of an alpha-adrenergic receptor antagonist and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined use of an alpha-adrenergic receptor antagonist and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2055597

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.